Lexaria Bioscience Corp. (Nasdaq: LEXX) has launched its 2026 research and development program aimed at expanding pharmaceutical, intellectual property, and business development opportunities through improved formulations. The company announced details of three representative studies that will occupy its primary focus through at least the first three quarters of the calendar year.
CEO Richard Christopher described the program as potentially "the most focused on practical results that the Company has ever conducted," with studies specifically concentrated on increasing the likelihood of pharmaceutical industry partnerships and creating new intellectual property. Some aspects of the work remain intentionally undisclosed as success could lead to expanded patent development.
The human study, designated GLP-1-H26-7, is expected to be a five-week parallel group study with three different arms. Primary goals include establishing safety, tolerability, and pharmacokinetic evaluation, comparing salcaprozate sodium-inclusive DehydraTECH-semaglutide tablet and capsule compositions to commercially available Wegovy semaglutide tablets under fasted conditions. This study expands upon findings from Human Pilot Study #1 which delivered promising pharmacokinetic and safety results but was limited to single-day dosing. The new study will target steady-state pharmacokinetic results with approximately 30 subjects in each tablet comparison arm and 15 subjects in the capsule arm, improving statistical reliability. Lexaria is working with third-party service providers to begin recruitment as early as April, with ethics board submissions pending and a final report expected in the fourth quarter of 2026.
Two animal studies complement the human research. Animal Study GLP-1-A26-1 will be a large, single-dose study with 8-11 different arms testing various SNAC-inclusive DehydraTECH-semaglutide formulations and DehydraTECH-cannabidiol formulations. A primary goal is discovering whether new formulation enhancements might improve pharmacokinetic performance for either drug class. Brain samples will be collected since DehydraTECH has previously demonstrated superior absorption of active ingredients into brain tissue, an area of particular interest given increasing understanding that GLP-1 drug performance involves brain neurochemistry. This study aims to create new intellectual property previously unknown to the industry for oral drug delivery technology.
Animal Study GLP-1-A26-2 will focus on delivering DehydraTECH-enhanced retatrutide and amycretin, both GLP-1 drugs Lexaria has never studied before. The inclusion of retatrutide marks the company's first work with a triple agonist targeting GLP-1, glucose-dependent insulinotropic polypeptide, and glucagon receptors. Some study arms will compare pharmacokinetic performance of test articles placed endoscopically in the intestine versus being swallowed to target the stomach, comparing formulation functionality in different gastrointestinal regions. Both animal studies are anticipated to begin in the second quarter of 2026 with final reports expected near the end of the third quarter.
These developments are significant because they represent a strategic push into the competitive GLP-1 drug market, which includes treatments for diabetes and obesity. Improved oral delivery systems could potentially address current limitations in drug absorption and side effects, creating opportunities for pharmaceutical partnerships. The research program's focus on brain tissue absorption is particularly noteworthy given emerging understanding of GLP-1 mechanisms involving central nervous system pathways. Success in these studies could position Lexaria's DehydraTECH technology as a valuable platform for next-generation oral medications, potentially impacting millions of patients who rely on GLP-1 therapies while creating new revenue streams through licensing and partnership agreements.
